Article Text

Download PDFPDF

Patient-reported gout attack frequency and allopurinol use in general practice in the Netherlands: a prospective observational cohort study protocol
  1. Kevin D B van Leeuwen1,
  2. Arthur M Bohnen1,
  3. Marloes L Jacobs1,
  4. Johan van Der Lei2,
  5. Hein J E M Janssens3,
  6. Aafke R Koffeman4,
  7. Patrick J E Bindels1,
  8. Sita M A Bierma-Zeinstra1
  1. 1 Department of General Practice, Erasmus Medical Center, Rotterdam, The Netherlands
  2. 2 Department of Medical Informatics, Erasmus Medical Center, Rotterdam, Netherlands
  3. 3 Department of General Practice, Radboud University Medical Center, Nijmegen, Netherlands
  4. 4 Department of Elderly Health, Leids Universitair Medisch Centrum, Leiden, Netherlands
  1. Correspondence to Kevin D B van Leeuwen; k.leeuwen{at}erasmusmc.nl

Abstract

Introduction Gout is the most common inflammatory arthritis in the Dutch general practice population and is often managed with long-term uric acid lowering treatment. The clinical relevance of this treatment in preventing gout attacks is unclear.

Primary research question What is the frequency of self-reported gout attacks and what is the effect of allopurinol use in patients diagnosed with gout in general practice?

Methods and analysis Adult patients with a diagnostic consultation code for gout in the year 2013, 2014 or 2015 will be invited to participate in this prospective observational cohort study. Patients with a limited life expectancy will be excluded. Baseline measurements will include blood pressure, body mass index and a blood sample (estimated glomerular filtration rate, serum uric acid, cholesterol (low-density lipoprotein (LDL) and high-density lipoprotein), glucose (fasting)). At the 2-year follow-up, patients will receive questionnaires every 3 months. The questionnaires at baseline, 12 months and 24 months assess the frequency of gout attacks, the presence of tophi, comorbidity, medication use, quality of life, diet and lifestyle. The questionnaires in between only assess the frequency of gout attacks and medication use for gout. Descriptive statistics will be used to calculate the mean frequency of self-reported gout attacks during the 2-year follow-up. The propensity score for each patient being offered allopurinol is estimated and used to match patients with and without allopurinol treatment. We will compare the frequency of gout attacks in these groups using multilevel Poisson regression analyses. With this type of analysis, we can calculate the corrected estimated effect of allopurinol on gout attack frequency.

Ethics and dissemination The research protocol was approved by the Medical Ethical Committee of the Erasmus Medical Centre in Rotterdam. The knowledge generated by this study will be transferred to the Dutch College of General Practitioners, conferences and to (inter)national peer-reviewed journals.

Trial registration number NTR6329; Pre-results.

  • rheumatology
  • general medicine (see internal medicine)
  • epidemiology

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors KDBvL, SMAB-Z and PJEB designed the study with input from all the authors. KDBvL drafted the manuscript under supervision of AMB, SMAB-Z and PJEB. AMB, MLJ, JvDL, HJEMJ and ARK significantly contributed to the establishment and refinement of study procedures and critically revised the manuscript. All authors approved the final version of the manuscript.

  • Funding This work was supported by the Netherlands Organisation for Health Research and Development (Zonmw, grant number 80-83910-98-13051).

  • Competing interests SMAB-Z is consultant for Infirst Healthcare. All other authors declare that they have no competing interests

  • Patient consent Not required.

  • Ethics approval Medical Ethical Committee, Erasmus MC, Rotterdam, the Netherlands.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.